Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group.

Autor: Umaretiya PJ; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Naranjo A; Children's Oncology Group Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA., Zhang FF; Children's Oncology Group Statistics and Data Center, Monrovia, California, USA., Irwin MS; Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada., DuBois SG; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Bagatell R; Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Bona K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Jul; Vol. 71 (7), pp. e31051. Date of Electronic Publication: 2024 May 05.
DOI: 10.1002/pbc.31051
Abstrakt: It is not clear whether trial access disparities exist in the Children's Oncology Group (COG). Here, we leverage a cohort of children with high-risk neuroblastoma (HR-NBL) enrolled on the COG ANBL00B1 neuroblastoma biology study to examine subsequent enrollment to upfront COG therapeutic trials by race, ethnicity, and proxied poverty status. Among 1917 children with HR-NBL enrolled on ANBL00B1, 696 (36.3%) subsequently enrolled on an upfront therapeutic trial with no difference by race, ethnicity, or proxied poverty status. In neuroblastoma, trial access disparities are not comparable to adult oncology, and efforts to advance equity should prioritize other mechanisms of survival disparities.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: